cat no | io1063, io1064, io1065
ioGlutamatergic Neurons APP V717I/V717I are opti‑ox™ precision reprogrammed glutamatergic neurons carrying a genetically engineered homozygous V717I mutation in the APP gene encoding amyloid precursor protein. These cells offer a rapidly maturing, disease relevant system for investigating the role of the APP London mutation in early-onset Alzheimer's disease (AD).
A selection of three clones is available, all genetically matched to the wild-type control, ioGlutamatergic Neurons™. This disease model is part of an Alzheimer's disease panel of physiologically relevant human iPSC-derived cells that can be incorporated into translational research and drug discovery workflows. Additional mutations include heterozygous APP V717I, heterozygous and homozygous APP KM670/671NL and PSEN1 M146L.
Confidently investigate your phenotype of interest across multiple clones with our disease model clone panel. Detailed characterisation data (below) and bulk RNA sequencing data (upon request) help you select specific clones if required.
per vial
A maximum number of 20 vials applies. If you would like to order more than 20 vials, please contact us at orders@bit.bio.
Make True Comparisons
Pair the ioDisease Model Cells with the genetically matched wild-type ioGlutamatergic Neurons to investigate the impact of the APP missense mutation on early-onset AD.
Scalable
With opti-ox technology, we can make billions of consistently reprogrammed cells, surpassing the demands of industrial workflows.
Quick
The disease model cells and isogenic control are experiment ready as early as 2 days post revival, and form structural neuronal networks at 11 days.
ioGlutamatergic Neurons APP V717I/V717I express neuron-specific markers comparably to the wild type control
ioGlutamatergic Neurons APP V717I/V717I form structural neuronal networks by day 11
ioGlutamatergic Neurons APP V717I/V717I demonstrate gene expression of neuronal-specific and glutamatergic-specific markers following reprogramming
Disease-related APP is expressed in ioGlutamatergic Neurons APP V717I/V717I following reprogramming
V9
bit.bio
2024
Professor Deepak Srivastava
Professor of Molecular Neuroscience and Group Leader, MRC Centre for Developmental Disorders
King’s College London
Emmanouil Metzakopian | Vice President, Research and Development | bit.bio
Javier Conde-Vancells | Director Product Management | bit.bio
Whitehouse, et al
JoVE Journal of Visualized Experiments
2023
Using ioGlutamatergic Neurons
Dr Ania Wilczynska | Head of Computational Genomics | Non-Clinical | bit.bio
Innovation showcase talk at ISSCR
Marius Wernig MD, PhD | Stanford
Mark Kotter, MD, PhD | bit.bio
Oosterveen, et al
bit.bio & Charles River Laboratories
2023
Mark Kotter | CEO and founder | bit.bio
Marius Wernig | Professor Departments of Pathology and Chemical and Systems Biology | Stanford University
Madeleine Garrett | Field Application Specialist | bit.bio
Ritsma et al
Charles River Laboratories & bit.bio
2022
Ritsma, et al
Charles River Laboratories & bit.bio
2022
Raman, et al
bit.bio
2022
bit.bio | MaxWell Biosystems | Charles River Laboratories
2022
Pavinlek, et al
Frontiers in Psychiatry
2022
Using ioGlutamatergic Neurons
Bando, et al
Frontiers in Cellular and Infection Microbiology
2022
Using ioGlutamatergic Neurons
Read this blog on glutamatergic neuron cell culture for our top tips on careful handling, cell plating and media changes to achieve success from the outset.
Further your disease research by pairing our wild type cells with isogenic disease models.